Latest News

Q3 2024 Watch monitoring HCV treatment access across ADAPs, Medicaid, Veterans programs, and assistance initiatives.

HCV co-infection in HIV-positive MSM: treatment barriers through ADAPs and policy recommendations.

Q2 2024 Watch: Prior authorization rollbacks in Medicaid HCV programs; ADAP and assistance program coverage.

Q1 2024 Watch: Pandemic Medicaid protections ended; millions lost coverage; ADAP and veterans updates.

Q4 2023 Watch: Bipartisan PEPFAR reauthorization push; ADAP coverage and Medicaid updates tracked.

Research proves alcohol doesn't reduce DAA efficacy for HCV, yet payers continue restricting treatment.

Q3 2023 Watch: HIV disparities coverage; debt ceiling crisis impacts; Medicaid disenrollment trends tracked.

Q2 2023 Watch: Braidwood decision impacts PrEP coverage; ADAP coverage analysis and Medicaid program updates.

Q1 2023 Watch: Tennessee rejecting federal HIV funding; updates on ADAPs, Medicaid, veterans care, and harm reduction.

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.

Only 35% of privately insured and 23% of Medicaid patients initiate HCV treatment due to payer barriers.

Q3 2022 review of HCV drug access across ADAPs, Medicaid, and comprehensive harm reduction programs.

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.

Study of 109,283 patients links HIV status and viral hepatitis coinfection to significantly increased liver cancer rates.

Supreme Court allows states to ration hepatitis C care in prisons, setting dangerous precedent for incarcerated people.

Quarterly update on HCV treatment coverage across ADAPs, Medicaid, Veterans programs, and patient assistance options.

Quarterly Watch covering HCV treatment access across ADAPs and Medicaid, harm reduction programs, and COVID-19 impact on care.